Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting13-03-2024
13-03-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)
Resignation of Chief Executive Officer (CEO)03-03-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting01-03-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting23-02-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Credit Rating
CARE Ratings Limited vide its letter dated February 14, 2024 re-affirmed the Credit Rating for the bank facilities of the Company.14-02-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of conference call on Financial Results for Q3 & 9M FY 2407-02-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings05-02-2024
Dr. Lal Pathlabs Q3 Results Review - Wait For Volume Recovery Getting Longer: Yes Securities
Profit after tax up 54% on lower interest expenses and higher other income YoY along with 300 basis points margin improvement YoY.02-02-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of financial results for Quarter and Nine Months ended December 31, 202302-02-2024
Hot Stocks: Brokerages view on Indian Hotels, Titan Company, Paytm and Dr Lal PathLabs
Goldman Sachs maintained a sell rating on Dr Lal PathLabs with a target price of Rs 2200. The company reported a subdued volume growth and the trend continues.02-02-2024